188 related articles for article (PubMed ID: 29801053)
1. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.
Richardson RC
JAMA Pediatr; 2018 Jul; 172(7):701. PubMed ID: 29801053
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
Prasad V
JAMA Pediatr; 2018 Jul; 172(7):701-702. PubMed ID: 29800980
[No Abstract] [Full Text] [Related]
3. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
Prasad V
JAMA Pediatr; 2018 Feb; 172(2):123-125. PubMed ID: 29228077
[No Abstract] [Full Text] [Related]
4. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
Lee M; França UL; Graham RJ; McManus ML
Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
[No Abstract] [Full Text] [Related]
5. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
6. [Nusinersen in the treatment of spinal muscular atrophy].
Sinkó G; Kiss Z; Kalman B
Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
[TBL] [Abstract][Full Text] [Related]
7. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
[TBL] [Abstract][Full Text] [Related]
13. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen for spinal muscular atrophy: Not just for babies?
Ciafaloni E; Russman BS
Neurology; 2019 May; 92(21):985-986. PubMed ID: 31019098
[No Abstract] [Full Text] [Related]
15. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
[No Abstract] [Full Text] [Related]
16. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
[No Abstract] [Full Text] [Related]
17. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
18. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen in adults with spinal muscular atrophy: new challenges.
Mercuri E; Sansone V
Lancet Neurol; 2020 Apr; 19(4):283-284. PubMed ID: 32199087
[No Abstract] [Full Text] [Related]
20. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
Corey DR
Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
[No Abstract] [Full Text] [Related]
[Next] [New Search]
